SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF), a Canadian life sciences company, has announced the initiation of a Good Laboratory Practice (GLP) toxicology and pharmacology program for its lead drug candidate GEP-44, a multi-receptor peptide targeting obesity and type 2 diabetes. This program is aligned with U.S. Food and Drug Administration (FDA) requirements and is intended to support an Investigational New Drug (IND) application, a necessary step before first-in-human clinical trials.
The company positions itself as an agile entrant in the rapidly expanding GLP-1 market, having developed a patented second-generation incretin-based therapy after securing licensing rights to the GEP-44 compound from Syracuse University. The move comes as the global GLP-1 receptor agonist market is projected to grow significantly, driven by increasing obesity rates and demand for more effective treatments.
Dr. Nihar Pandey, Chief Scientific Officer at SureNano, stated that the program marks a transition toward clinical-stage evaluation. "Initiating these U.S. Food and Drug Administration IND-enabling studies is a major milestone for SureNano Science and GlucaPharm, moving us firmly towards the final, rigorous evaluation in various clinical phases before entering the clinic," said Dr. Pandey. "Partnering with a globally renowned CRO like LabCorp will ensure our studies meet the highest regulatory standards. This package is vital to de-risk our lead candidate and is designed to support our strategy of launching a Phase I clinical trial in Australia."
The full article can be viewed at https://ibn.fm/78hI3. SureNano Science has acquired GlucaPharm Inc., a next-generation GLP-1 pharmaceutical company developing GEP44, a patented peptide targeting obesity and metabolic disorders with improved tolerability and potential non-injectable delivery. The company's initial business involves the sale and distribution of the SureNano(TM) surfactant, a ready-to-mix food grade compound for high-performance nanoemulsions, with exclusive licenses in Canada, Oklahoma, and Colorado. However, the company is now pivoting to become a pharmaceutical-focused entity through the advancement of this therapeutic candidate.
The implications of this announcement are significant for the biotech and pharmaceutical sectors. As obesity and type 2 diabetes continue to pose major global health challenges, next-generation therapies like GEP-44 could offer improved efficacy and tolerability over existing treatments. The initiation of FDA-aligned preclinical studies not only de-risks the candidate but also signals a clear pathway toward clinical development. Furthermore, the partnership with LabCorp, a globally recognized contract research organization, underscores the company's commitment to high regulatory standards and enhances the credibility of the preclinical program.
For investors, this development positions SureNano Science as a potential player in the lucrative GLP-1 market, which has seen blockbuster drugs like semaglutide driving significant revenue. The company's strategy to conduct Phase I trials in Australia, known for efficient regulatory processes, could accelerate time-to-market and reduce costs. Additionally, the focus on non-injectable delivery could differentiate GEP-44 from current injectable therapies, potentially capturing a larger patient population.
More information about SureNano Science is available at their newsroom at https://ibn.fm/SURNF.
